Most global shares edged higher this morning on hopes for a virus vaccine, even though worries about the pandemic’s long-term economic damage remain strong. It’s reported that Pfizer’s vaccine is on schedule for regulatory review in October, boosting investor sentiment. Additionally, a remark from China’s Commerce Ministry that China and […]